{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:52:29Z","timestamp":1790401949634,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","award":["postdoctoral award"],"award-info":[{"award-number":["postdoctoral award"]}],"id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure","doi-asserted-by":"publisher","award":["postdoctoral award"],"award-info":[{"award-number":["postdoctoral award"]}],"id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA174929"],"award-info":[{"award-number":["CA174929"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA122216"],"award-info":[{"award-number":["CA122216"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004802","name":"California Breast Cancer Research Program","doi-asserted-by":"publisher","award":["18IB-0150"],"award-info":[{"award-number":["18IB-0150"]}],"id":[{"id":"10.13039\/100004802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004802","name":"California Breast Cancer Research Program","doi-asserted-by":"publisher","award":["16OB-0150"],"award-info":[{"award-number":["16OB-0150"]}],"id":[{"id":"10.13039\/100004802","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10549-016-3698-y","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T08:33:01Z","timestamp":1455006781000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effective treatment of HER2-amplified breast cancer by targeting HER3 and \u03b21 integrin"],"prefix":"10.1007","volume":"155","author":[{"given":"Marcia R.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Ziaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ruiz-Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Gulizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Oeffinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhara N.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Moasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,9]]},"reference":[{"issue":"56","key":"3698_CR1","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","volume":"19","author":"J Mendelsohn","year":"2000","unstructured":"Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19(56):6550\u20136565","journal-title":"Oncogene"},{"issue":"10","key":"3698_CR2","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","volume":"65","author":"MJ Wieduwilt","year":"2008","unstructured":"Wieduwilt MJ, Moasser MM (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65(10):1566\u20131584. doi: 10.1007\/s00018-008-7440-8","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"3698_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9\u201322. doi: 10.1038\/nrc2748","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3698_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10555-010-9211-x","volume":"29","author":"R Rathinam","year":"2010","unstructured":"Rathinam R, Alahari SK (2010) Important role of integrins in the cancer biology. Cancer metastasis reviews 29(1):223\u2013237. doi: 10.1007\/s10555-010-9211-x","journal-title":"Cancer metastasis reviews"},{"issue":"10","key":"3698_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nrd3266","volume":"9","author":"D Cox","year":"2010","unstructured":"Cox D, Brennan M, Moran N (2010) Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 9(10):804\u2013820. doi: 10.1038\/nrd3266","journal-title":"Nat Rev Drug Discov"},{"key":"3698_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-4419-6066-5_5","volume":"674","author":"S Cabodi","year":"2010","unstructured":"Cabodi S, Di Stefano P, Leal Mdel P, Tinnirello A, Bisaro B, Morello V, Damiano L, Aramu S, Repetto D, Tornillo G, Defilippi P (2010) Integrins and signal transduction. Adv Exp Med Biol 674:43\u201354","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"3698_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/jcp.22183","volume":"224","author":"J Beattie","year":"2010","unstructured":"Beattie J, McIntosh L, van der Walle CF (2010) Cross-talk between the insulin-like growth factor (IGF) axis and membrane integrins to regulate cell physiology. J Cell Physiol 224(3):605\u2013611. doi: 10.1002\/jcp.22183","journal-title":"J Cell Physiol"},{"issue":"3","key":"3698_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1042\/BJ20081948","volume":"418","author":"CH Streuli","year":"2009","unstructured":"Streuli CH, Akhtar N (2009) Signal co-operation between integrins and other receptor systems. Biochem J 418(3):491\u2013506. doi: 10.1042\/bj20081948","journal-title":"Biochem J"},{"issue":"35","key":"3698_CR9","doi-asserted-by":"publisher","first-page":"15559","DOI":"10.1073\/pnas.1003034107","volume":"107","author":"L Huck","year":"2010","unstructured":"Huck L, Pontier SM, Zuo DM, Muller WJ (2010) \u03b21-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci 107(35):15559\u201315564. doi: 10.1073\/pnas.1003034107","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"3698_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cell.2006.05.047","volume":"126","author":"W Guo","year":"2006","unstructured":"Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG (2006) Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 126(3):489\u2013502. doi: 10.1016\/j.cell.2006.05.047","journal-title":"Cell"},{"issue":"5","key":"3698_CR11","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-09-1218","volume":"16","author":"MR Campbell","year":"2010","unstructured":"Campbell MR, Amin D, Moasser MM (2010) HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16(5):1373\u20131383. doi: 10.1158\/1078-0432.ccr-09-1218","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3698_CR12","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1128\/MCB.14.6.3550","volume":"14","author":"SP Soltoff","year":"1994","unstructured":"Soltoff SP, Carraway KL 3rd, Prigent SA, Gullick WG, Cantley LC (1994) ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14(6):3550\u20133558","journal-title":"Mol Cell Biol"},{"key":"3698_CR13","doi-asserted-by":"publisher","first-page":"21608","DOI":"10.1073\/pnas.0912101106","volume":"106","author":"N Jura","year":"2009","unstructured":"Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J (2009) Structural analysis of the catalytically inactive kinase domain of the human HER3 receptor. Proc Nat Acad Sci USA 106:21608\u201321613","journal-title":"Proc Nat Acad Sci USA"},{"issue":"15","key":"3698_CR14","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1073\/pnas.1537685100","volume":"100","author":"T Holbro","year":"2003","unstructured":"Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE (2003) The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100(15):8933\u20138938","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"3698_CR15","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","volume":"68","author":"ST Lee-Hoeflich","year":"2008","unstructured":"Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68(14):5878\u20135887","journal-title":"Cancer Res"},{"issue":"10","key":"3698_CR16","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1158\/0008-5472.CAN-11-3594","volume":"72","author":"DB Vaught","year":"2012","unstructured":"Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sanchez V, Koland J, Muller WJ, Arteaga CL, Cook RS (2012) HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res 72(10):2672\u20132682. doi: 10.1158\/0008-5472.can-11-3594","journal-title":"Cancer Res"},{"issue":"7126","key":"3698_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature05474","volume":"445","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445(7126):437\u2013441","journal-title":"Nature"},{"key":"3698_CR18","doi-asserted-by":"publisher","unstructured":"Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM (2010) Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2(16):16ra17. doi: 10.1126\/scitranslmed.3000389","DOI":"10.1126\/scitranslmed.3000389"},{"issue":"12","key":"3698_CR19","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.1016140108","volume":"108","author":"JT Garrett","year":"2011","unstructured":"Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 108(12):5021\u20135026. doi: 10.1073\/pnas.1016140108","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3698_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10549-009-0502-2","volume":"122","author":"B Weigelt","year":"2010","unstructured":"Weigelt B, Lo A, Park C, Gray J, Bissell M (2010) HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 122(1):35\u201343. doi: 10.1007\/s10549-009-0502-2","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"3698_CR21","doi-asserted-by":"publisher","first-page":"R84","DOI":"10.1186\/bcr2936","volume":"13","author":"C Huang","year":"2011","unstructured":"Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R (2011) beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res 13(4):R84. doi: 10.1186\/bcr2936","journal-title":"Breast Cancer Res"},{"issue":"3","key":"3698_CR22","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/0008-5472.CAN-05-3071","volume":"66","author":"CC Park","year":"2006","unstructured":"Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ (2006) \u03b21 Integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66(3):1526\u20131535. doi: 10.1158\/0008-5472.can-05-3071","journal-title":"Cancer Res"},{"issue":"23","key":"3698_CR23","doi-asserted-by":"crossref","first-page":"17597","DOI":"10.1016\/S0021-9258(19)85374-7","volume":"268","author":"Y Takada","year":"1993","unstructured":"Takada Y, Puzon W (1993) Identification of a regulatory region of integrin beta 1 subunit using activating and inhibiting antibodies. J Biol Chem 268(23):17597\u201317601","journal-title":"J Biol Chem"},{"issue":"25","key":"3698_CR24","doi-asserted-by":"publisher","first-page":"14821","DOI":"10.1073\/pnas.95.25.14821","volume":"95","author":"F Wang","year":"1998","unstructured":"Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, Bissell MJ (1998) Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 95(25):14821\u201314826","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3698_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1083\/jcb.137.1.231","volume":"137","author":"VM Weaver","year":"1997","unstructured":"Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137(1):231\u2013245","journal-title":"J Cell Biol"},{"issue":"1","key":"3698_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1746-1596-7-104","volume":"7","author":"P dos Santos","year":"2012","unstructured":"dos Santos P, Zanetti J, Ribeiro-Silva A, Beltrao E (2012) Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagnostic Pathology 7(1):104","journal-title":"Diagnostic Pathology"},{"issue":"8","key":"3698_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3816\/CBC.2007.n.017","volume":"7","author":"MS Ewer","year":"2007","unstructured":"Ewer MS, O\u2019Shaughnessy JA (2007) Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 7(8):600\u2013607","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"3698_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5):459\u2013465. doi: 10.1038\/nm0502-459","journal-title":"Nat Med"},{"issue":"6","key":"3698_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1161\/01.RES.87.6.508","volume":"87","author":"LK Hornberger","year":"2000","unstructured":"Hornberger LK, Singhroy S, Cavalle-Garrido T, Tsang W, Keeley F, Rabinovitch M (2000) Synthesis of extracellular matrix and adhesion through beta(1) integrins are critical for fetal ventricular myocyte proliferation. Circ Res 87(6):508\u2013515","journal-title":"Circ Res"},{"issue":"4","key":"3698_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/hh0402.105790","volume":"90","author":"SY Shai","year":"2002","unstructured":"Shai SY, Harpf AE, Babbitt CJ, Jordan MC, Fishbein MC, Chen J, Omura M, Leil TA, Becker KD, Jiang M, Smith DJ, Cherry SR, Loftus JC, Ross RS (2002) Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure. Circ Res 90(4):458\u2013464","journal-title":"Circ Res"},{"issue":"2","key":"3698_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cell.2009.04.060","volume":"138","author":"K Bersell","year":"2009","unstructured":"Bersell K, Arab S, Haring B, Kuhn B (2009) Neuregulin1\/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138(2):257\u2013270. doi: 10.1016\/j.cell.2009.04.060","journal-title":"Cell"},{"issue":"17","key":"3698_CR32","doi-asserted-by":"publisher","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","volume":"273","author":"YY Zhao","year":"1998","unstructured":"Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA (1998) Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273(17):10261\u201310269","journal-title":"J Biol Chem"},{"issue":"6555","key":"3698_CR33","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/378390a0","volume":"378","author":"M Gassmann","year":"1995","unstructured":"Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G (1995) Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378(6555):390\u2013394. doi: 10.1038\/378390a0","journal-title":"Nature"},{"issue":"5","key":"3698_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/ncb3149","volume":"17","author":"G D\u2019Uva","year":"2015","unstructured":"D\u2019Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S, Weisinger K, Bassat E, Rajchman D, Yifa O, Lysenko M, Konfino T, Hegesh J, Brenner O, Neeman M, Yarden Y, Leor J, Sarig R, Harvey RP, Tzahor E (2015) ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat Cell Biol 17(5):627\u2013638. doi: 10.1038\/ncb3149","journal-title":"Nat Cell Biol"},{"issue":"6","key":"3698_CR35","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1158\/0008-5472.CAN-09-3145","volume":"70","author":"B Schoeberl","year":"2010","unstructured":"Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK (2010) An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 70(6):2485\u20132494. doi: 10.1158\/0008-5472.can-09-3145","journal-title":"Cancer Res"},{"issue":"1","key":"3698_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-011-1908-1","volume":"134","author":"E Blackburn","year":"2012","unstructured":"Blackburn E, Zona S, Murphy ML, Brown IR, Chan SK, Gullick WJ (2012) A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines. Breast Cancer Res Treat 134(1):53\u201359. doi: 10.1007\/s10549-011-1908-1","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3698_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1158\/1535-7163.MCT-11-0820","volume":"11","author":"CF McDonagh","year":"2012","unstructured":"McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB (2012) Antitumor activity of a novel bispecific antibody that targets the ErbB2\/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 11(3):582\u2013593. doi: 10.1158\/1535-7163.mct-11-0820","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"3698_CR38","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1158\/0008-5472.CAN-13-1198","volume":"73","author":"AP Garner","year":"2013","unstructured":"Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA (2013) An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 73(19):6024\u20136035. doi: 10.1158\/0008-5472.can-13-1198","journal-title":"Cancer Res"},{"key":"3698_CR39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-0464","author":"CH Kugel 3rd","year":"2014","unstructured":"Kugel CH 3rd, Hartsough EJ, Davies MA, Setiady YY, Aplin AE (2014) Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. doi: 10.1158\/0008-5472.can-14-0464","journal-title":"Cancer Res"},{"issue":"4","key":"3698_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.chembiol.2014.02.011","volume":"21","author":"P Littlefield","year":"2014","unstructured":"Littlefield P, Moasser MM, Jura N (2014) An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chem Biol 21(4):453\u2013458. doi: 10.1016\/j.chembiol.2014.02.011","journal-title":"Chem Biol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3698-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-016-3698-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3698-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3698-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T18:15:56Z","timestamp":1654280156000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-016-3698-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["3698"],"URL":"https:\/\/doi.org\/10.1007\/s10549-016-3698-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"23 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CP is co-founder of Oncosynergy, Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}